Stock & Company Details
Axsome Therapeutics Inc $AXSM
Price:
N/A
N/A
52M
$8.9B
52 Week High:
N/A
10 Day Average Volume:
N/A
-45.49
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
AXSM technical indicators
Latest Axsome Therapeutics Inc (AXSM) indicator readings as of 2026-10-09.
AXSM's 14-day RSI is 22.7, in oversold territory. At $168.35 it is trading 16.0% below its 200-day moving average of $200.36, and below its 50-day average of $203.16. Price sits near the lower Bollinger Band ($161.75 to $221.89). ADX reads 34.1, indicating a trending market.
AXSM backtested strategy results
How 4 rule-based strategies performed on Axsome Therapeutics Inc (AXSM) over recent history, last backtested 2026-10-08. Select a strategy to plot its trades on the chart above. Past performance does not predict future results.
| Strategy | Equity curve | Return | Win rate | Trades | Max drawdown |
|---|---|---|---|---|---|
| Oversold Bounce Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | +257.2% | 58% | 12 | -32.7% | |
| Momentum Crossover Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | -9.9% | 34% | 32 | -61.7% | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | +66.8% | 47% | 30 | -33.8% | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | -11.4% | 56% | 32 | -66.9% |
Overview
Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption of life-changing medicines. Axsome's core CNS product candidate portfolio includes five clinical-stage candidates, AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14. AXS-05 is being developed for major depressive disorder (MDD), Alzheimer's disease (AD) agitation, and as a treatment for smoking cessation. AXS-07 is being developed for the acute treatment of migraine. AXS-12 is being developed for the treatment of narcolepsy. AXS-14 is being developed for fibromyalgia. AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14 are investigational drug products not approved by the FDA.
Finance Bot
Ask your questions
Start by typing a question below.
